← Trials/Trial dossier/NCT01002300

CompletedPhase NA

Oxytocin and Social Cognition in Frontotemporal Dementia

Investigation of the Effects of Intranasal Oxytocin on Cognition and Emotion Processing in Frontotemporal Dementia

Lead sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Asset

Oxytocin

Listed sites

Recruiting sites

Enrollment

actual

Study population

Frontotemporal dementia

Key I/E criterion

•Age 30-80

Primary endpoint

•Performance on Emotion Recognition Tasks

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Secondary15398

NCT IDNCT01002300

Org study IDR-08-395

Timeline

Milestones

Study start2009-09 (month precision)

Study first posted2009-10-27estimated

Primary completion2010-11actual (month precision)

Study completion2010-11actual (month precision)

Last update posted2014-03-18estimated

Assets

Drug assets

Oxytocin

Study populations

Who this study enrolls

Frontotemporal dementia

Eligibility

Who can enroll

Minimum age30 Years

Maximum age80 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Clinical diagnosis of probable Frontotemporal Dementia or Pick's disease

•Caregiver available to participate in all study visits

Exclusion criteria

•Severe language or memory deficits that preclude completion of the cognitive tasks

•Females who are pregnant or breastfeeding (a pregnancy test will be done on females who have not completed menopause)

•Uncontrolled hypertension

•Bradycardia (rate <50 bpm) or tachycardia (rate > 100 bpm)

•Current use of prostaglandins

•Use of any investigational or experimental drug or device within the last 60 days prior to screening or within 5 half-lives of the experimental drug , whichever is longer

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Memory

1 endpoint

Primary/protocol endpoint

Performance on Emotion Recognition Tasks

Time frame:Day of treatment

descriptive

Other (unclassified)

2 endpoints

Secondary/protocol endpoint/low confidence

Behavioural Ratings of Emotional Sensitivity and Repetitive Behaviours

Time frame:One week following treatment

descriptive

Secondary/protocol endpoint/low confidence

Side effects

Time frame:1 week after treatment

descriptive

Publications (3)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.